Antithrombotic therapy in PCI: why not heparin?

EuroIntervention. 2013 Aug 22;9(4):423-6. doi: 10.4244/EIJV9I4A69.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Abciximab
  • Antibodies, Monoclonal / therapeutic use*
  • Anticoagulants / therapeutic use*
  • Antithrombins / therapeutic use*
  • Female
  • Heparin / therapeutic use*
  • Hirudins
  • Humans
  • Immunoglobulin Fab Fragments / therapeutic use*
  • Male
  • Myocardial Infarction / therapy*
  • Peptide Fragments / therapeutic use*
  • Platelet Aggregation Inhibitors / therapeutic use*
  • Recombinant Proteins / therapeutic use

Substances

  • Antibodies, Monoclonal
  • Anticoagulants
  • Antithrombins
  • Hirudins
  • Immunoglobulin Fab Fragments
  • Peptide Fragments
  • Platelet Aggregation Inhibitors
  • Recombinant Proteins
  • Heparin
  • bivalirudin
  • Abciximab